GSK plc (GSK) Form 6-K — Jul 22, 2026
GSK plc announced that the US Food and Drug Administration has approved Jideytro (zidesamtinib) for the treatment of adult patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer who have previously received a ROS1 kinase inhibitor. This approval represents GSK's first medicine approved for lung cancer and was granted ahead of the scheduled target action date. The approval is supported by data from the ARROS-1 phase I/II trial, which reported an objective response rate of 44% in 117 patients with advanced disease.
Key figures
- Or Rate
- 44%
- Dor Six Months
- 82%
- Dor Twelve Months
- 69%
- Safety Population Size
- 446
- Efficacy Population Size
- 117
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.